Log in

NYSE:NVSNovartis Stock Price, Forecast & News

$82.43
+0.04 (+0.05 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$82.33
Now: $82.43
$83.61
50-Day Range
$82.14
MA: $86.00
$90.46
52-Week Range
$69.18
Now: $82.43
$99.84
Volume1.65 million shs
Average Volume2.23 million shs
Market Capitalization$188.66 billion
P/E Ratio26.25
Dividend Yield2.44%
Beta0.46
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; Conatus Pharmaceuticals Inc.; and TRIO. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Read More
Novartis logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.3Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.83 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone41-61-324-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$47.50 billion
Cash Flow$7.85 per share
Book Value$24.53 per share

Profitability

Net Income$11.73 billion

Miscellaneous

Employees103,914
Outstanding Shares2,288,700,000
Market Cap$188.66 billion
Next Earnings Date10/27/2020 (Estimated)
OptionableOptionable
$82.43
+0.04 (+0.05 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novartis (NYSE:NVS) Frequently Asked Questions

How has Novartis' stock price been impacted by Coronavirus?

Novartis' stock was trading at $82.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVS stock has increased by 0.4% and is now trading at $82.43.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Novartis?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novartis
.

When is Novartis' next earnings date?

Novartis is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Novartis
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) issued its quarterly earnings results on Tuesday, July, 21st. The company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. The firm had revenue of $11.35 billion for the quarter, compared to analysts' expectations of $11.77 billion. Novartis had a return on equity of 24.14% and a net margin of 14.96%. The business's revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.34 EPS.
View Novartis' earnings history
.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Monday, February 3rd. Shareholders of record on Wednesday, March 4th will be given a dividend of $3.0425 per share on Thursday, March 12th. This represents a yield of 2%. The ex-dividend date is Tuesday, March 3rd. This is an increase from Novartis's previous annual dividend of $2.86.
View Novartis' dividend history
.

What price target have analysts set for NVS?

9 brokerages have issued 1 year target prices for Novartis' shares. Their forecasts range from $100.00 to $116.00. On average, they expect Novartis' share price to reach $108.00 in the next year. This suggests a possible upside of 31.0% from the stock's current price.
View analysts' price targets for Novartis
.

Has Novartis been receiving favorable news coverage?

Media stories about NVS stock have trended extremely negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novartis earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
View the latest news about Novartis
.

Are investors shorting Novartis?

Novartis saw a decline in short interest in February. As of February 15th, there was short interest totaling 3,270,000 shares, a decline of 18.9% from the January 31st total of 4,030,000 shares. Based on an average daily trading volume, of 1,880,000 shares, the days-to-cover ratio is presently 1.7 days. Currently, 0.1% of the company's shares are short sold.
View Novartis' Short Interest
.

Who are some of Novartis' key competitors?

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

Who are Novartis' key executives?

Novartis' management team includes the following people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 43)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 54)
  • Mr. Steffen Lang, Global Head of Technical Operations (Age 52)
  • Ms. Shannon Thyme Klinger, Group Gen. Counsel (Age 48)
  • Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 51)

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.39%), Schafer Cullen Capital Management Inc (0.10%), Manning & Napier Group LLC (0.09%), Principal Financial Group Inc. (0.06%), Scharf Investments LLC (0.06%) and Raymond James & Associates (0.06%).

Which institutional investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Fort Washington Investment Advisors Inc. OH, Rockefeller Capital Management L.P., Macquarie Group Ltd., Schafer Cullen Capital Management Inc, Cullen Capital Management LLC, Manning & Napier Group LLC, Bank of New York Mellon Corp, and D.A. Davidson & CO..

Which institutional investors are buying Novartis stock?

NVS stock was acquired by a variety of institutional investors in the last quarter, including TCTC Holdings LLC, Fisher Asset Management LLC, Envestnet Asset Management Inc., Scotia Capital Inc., Live Oak Private Wealth LLC, SG Americas Securities LLC, Ensign Peak Advisors Inc, and Tocqueville Asset Management L.P..

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $82.43.

How big of a company is Novartis?

Novartis has a market capitalization of $188.66 billion and generates $47.50 billion in revenue each year. The company earns $11.73 billion in net income (profit) each year or $5.24 on an earnings per share basis. Novartis employs 103,914 workers across the globe.

What is Novartis' official website?

The official website for Novartis is www.novartis.com.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.